The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

fulgentgenetics.com

Stage

IPO | IPO

Total Raised

$29.42M

Date of IPO

9/29/2016

Market Cap

1.51B

Stock Price

49.96

Revenue

$0000 

About Fulgent Genetics

Fulgent Genetics (Fulgent Therapeutics), is a technology company with an initial focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the overall quality of patient care. The company has developed a technology platform that integrates sophisticated data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. This platform allows Fulgent to offer a broad and flexible test menu while maintaining accessible pricing, high accuracy and competitive turnaround times.

Fulgent Genetics Headquarter Location

4978 Santa Anita Ave. Suite 205

Temple City, California, 91780,

United States

626-350-0537

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Fulgent Genetics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Fulgent Genetics is included in 5 Expert Collections, including Medical Devices.

M

Medical Devices

8,298 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health Monitoring & Diagnostics

2,598 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

O

Omics

1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

D

Digital Health

13,066 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

H

Health IT

7,900 items

Fulgent Genetics Patents

Fulgent Genetics has filed 5 patents.

The 3 most popular patent topics include:

  • Mitotic inhibitors
  • Polymers
  • Taxanes
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/22/2018

Taxanes, Mitotic inhibitors, Ion channels, Polymers, Acetate esters

Application

Application Date

7/22/2018

Grant Date

Title

Related Topics

Taxanes, Mitotic inhibitors, Ion channels, Polymers, Acetate esters

Status

Application

Latest Fulgent Genetics News

Global NGS Newborn Genetic Testing /Screening Market Size

Jun 6, 2022

Ltd, BGI, PerkinElmer Genomics, CENTOGENE N.V., CryoCell International, Fulgent Genetics, Igenomix, Veritas Intercontinental, GENEPATH, and MedGenome among others, are some of the key players operating the in the NGS newborn genetic testing /screening market. June 06, 2022 11:58 ET Mumbai, INDIA Brooklyn, New York, June 06, 2022 (GLOBE NEWSWIRE) -- According to a new market research report published by Global Market Estimates, the Global NGS Newborn Genetic Testing /Screening Market is projected to grow at a CAGR of 17.5% from 2022 to 2027. Declining sequencing prices, expanding knowledge pertaining to human genetics, the growing popularity of targeted therapies, and improved genomic data management are some of the key factors that are driving market revenue. Key Market Insights As per the application outlook, the inherited & other disorders screening/ testing segment is estimated as the highest revenue-generating segment in the 2021 NGS newborn genetic testing /screening market Based on the sample type outlook, the Blood segment is estimated to dominate the 2021 global market in terms of revenue generation Among the end-users, hospitals & clinics are estimated to capture maximum revenue share in the 2021 market North America (the United States, Canada, and Mexico) market is estimated to account for a major revenue share in the global NGS newborn genetic testing /screening market from 2022 to 2027 The Asia Pacific is expected to serve as the fastest revenue-generating market during the forecast period LifeCell International Pvt. Ltd, BGI, PerkinElmer Genomics, CENTOGENE N.V., CryoCell International, Fulgent Genetics, Igenomix, Veritas Intercontinental, GENEPATH, and MedGenome among others, are some of the key players in the NGS newborn genetic testing /screening market Request a Sample Copy of the report @ https://www.globalmarketestimates.com/market-report/ngs-newborn-genetic-testing-screening-market-3831 Sample Type Outlook (Revenue, USD Million, 2022-2027) Blood Inherited & Other Disorders Screening/ Testing Pharmacogenomics Hospitals & Clinics

Fulgent Genetics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Fulgent Genetics Rank

  • Where is Fulgent Genetics's headquarters?

    Fulgent Genetics's headquarters is located at 4978 Santa Anita Ave., Temple City.

  • What is Fulgent Genetics's latest funding round?

    Fulgent Genetics's latest funding round is IPO.

  • How much did Fulgent Genetics raise?

    Fulgent Genetics raised a total of $29.42M.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.